Moderna Inc. (MRNA)
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance
Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative. The post Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance appeared first on Investor's Business Daily.
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives
Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.
Moderna stock plunges 18% after company lowers 2025 sales forecast by $1 billion
Moderna lowered its 2025 sales guidance by roughly $1 billion, as it continues to cut costs. The biotech company now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half of the year.
Moderna's stock tumbles to post-COVID lows after revenue outlook disappoints
Moderna's stock tumbles after a disappointing outlook for revenue and the need to accelerate its cost-cutting plan.
Moderna Stock Sinks. It Disappoints With Covid-19 Vaccine Forecast.
The company said Monday that it expects 2025 revenue of between $1.5 billion and $2.5 billion.
Moderna cuts 2025 sales view on slow start to RSV shot, weak COVID vaccine demand
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow launch of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines.
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) Updates 2025 expected revenue range to $1.5 to 2.5 billion Expects to reduce 2025 cash cost expenses by $1.0 billion with a plan for additional 2026 cost reductions of $0.5 billion Updates 2025 expected ending cash balance to approximately $6.0 billion Anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts CAMBRIDGE, MA / ACCESSWIRE / January 13, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced business updates and progress across its pipeline of mRNA medicines. Moderna enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need.
Moderna Shares Spike on H5N1 News—What's Next for Investors?
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Why Did Moderna Stock Rise 12%?
The stock price of Moderna saw a 12% jump on Tuesday, January 7, amid rising cases of Covid-19 and flu in the U.S. Along with Moderna, stocks of other vaccine makers also saw an uptick. Novavax was up 11%, while BioNTech ADR was up 5%.
Here's why vaccine stocks are surging in 2025
After undergoing years of stock market decline as reporting and awareness about the COVID-19 pandemic subsided, major vaccine stocks received a major, if grim, boost in early 2025.
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Moderna Price Levels to Watch After Stock's 12% Surge on Tuesday
Moderna (MRNA) shares soared Tuesday as investors placed bets that the pharmaceutical giant's development of an H5N1 bird flu vaccine could boost sales after the first death linked to the disease was reported in the U.S this week.
